Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

A closing highlight of the programme is the joint symposium for all European Amgen Scholars in Cambridge, UK. In addition to conducting hands-on research, you will attend workshops and events offering ...

Elsewhere, Stoboclo and Osenvelt have received regulatory endorsements in the European Union and Korea. Amgen’s Prolia and Xgeva were initially approved in 2010 to treat osteoporosis and ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

Amgen investors are focused on prospects for ... for tobacco-style cancer warning labels on alcoholic drinks across Europe 4:15 PM UTC Elon Musk's artificial intelligence startup xAI is discussing ...

Shares of biotech company Amgen (NASDAQ:AMGN) jumped 5.3% in the morning session after the company reported strong fourth-quarter results. Amgen exceeded analysts' revenue expectations this ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...